Platinum

Generic Name: Platinum

Drug Type: Small Molecule

Chemical Formula: Pt

CAS Number: 7440-06-4

Unique Ingredient Identifier: 49DFR088MY

Background: Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.

Clinical Trials

Trial of BMS-986012 in Combination With Platinum and Etoposide

Phase 1

Active, not recruiting

Conditions: Small Cell Lung Cancer

Interventions: Drug: BMS-986012
Drug: Etoposide
Drug: Cisplatin
Drug: Platinum
Drug: Carboplatin

First Posted Date: 2016-06-28

Last Posted Date: 2024-05-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT02815592

Locations: 🇪🇸
Local Institution - 0002, Barcelona, Spain
🇪🇸
Local Institution - 0004, Madrid, Spain
🇪🇸
Local Institution - 0010, Malaga, Spain

and more 1 locations

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Platinum Doublet Chemotherapy

First Posted Date: 2016-01-20

Last Posted Date: 2023-04-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 324

Registration Number: NCT02659059

Locations: 🇺🇸
Local Institution - 0010, Mineola, New York, United States
🇨🇦
Local Institution - 0022, Kingston, Ontario, Canada
🇺🇸
Local Institution - 0015, Lincoln, Nebraska, United States

and more 29 locations

Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

Phase 2

Conditions: Breast Neoplasms

Interventions: Drug: EndostarTM Injection
Drug: Gemcitabine
Drug: Navelbine
Drug: Platinum

First Posted Date: 2015-07-03

Last Posted Date: 2017-07-17

Lead Sponsor: Xinjiang Medical University

Target Recruit Count: 120

Registration Number: NCT02489409

Locations: 🇨🇳
Third Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: AZD2014
Drug: Anthracyclines
Drug: MEDI4736
Drug: AZD4547
Drug: Taxanes
Drug: AZD5363
Drug: cyclophosphamide
Drug: DNA intercalators
Drug: AZD8931
Drug: Selumetinib
Drug: Methotrexate
Drug: vinca alkaloids
Drug: Vandetanib
Drug: Platinum based chemotherapies
Drug: Bicalutamide
Drug: Olaparib
Drug: Bevacizumab
Drug: Mitomycin C
Drug: Eribulin

First Posted Date: 2014-11-24

Last Posted Date: 2025-01-15

Lead Sponsor: UNICANCER

Target Recruit Count: 1460

Registration Number: NCT02299999

Locations: 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
Hopitaux Du Leman, Thonon-les-Bains, France

and more 21 locations